Nivolumab and Imiquimod for vulvar cancer patients
Treatments studied
Part of Cancer clinical trials.
This trial tests combining two drugs, nivolumab (an immunotherapy) and imiquimod (a cream that boosts the immune system), to treat vulvar squamous cell carcinoma. It aims to shrink tumors before surgery and may be an option for women with large or multifocal tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 or older.
- You have vulvar squamous cell carcinoma that is stage I to III and can be measured on a scan or exam.
- Your tumor is either larger than 4 cm, or there are multiple separate tumors on the vulva (at least one at least 1 cm), or any tumor where surgery would cause significant harm.
- You have not had prior treatment with drugs like nivolumab, pembrolizumab, or similar immune checkpoint inhibitors.
- Your overall health is good enough for daily activities (ECOG score 0–2).
- You have adequate kidney, liver, and blood cell counts as shown by recent lab tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is for people with early-stage vulvar cancer that can be surgically removed. It looks at the cancer's HPV and p53 status to decide how much tissue to remove, aiming to reduce side effects while keeping the cancer away.
This trial tests whether combining pembrolizumab with lenvatinib can shrink and control advanced vulvar squamous cell cancer that can’t be fully treated with surgery or strong radiation. It may help some people live longer and better control symptoms, but it also requires close monitoring and specific health criteria.
This trial tests a combination of two drugs, pembrolizumab (an immunotherapy) and lenvatinib (a targeted therapy), for women with advanced vulvar cancer that cannot be surgically removed or has spread. The goal is to see if this combination can shrink or control the cancer.
This trial tests a combination of an HPV vaccine, an immune cream (imiquimod), and a diabetes drug (metformin) together with standard chemoradiation. The goal is to see if this mix helps treat advanced cervical, vaginal, or vulvar cancers better than standard care alone.
This Phase 2 trial compares two treatment approaches for some women with vulvar squamous cell cancer: chemoradiation first, or chemotherapy first followed by surgery. The goal is to see which strategy works better or is safer for tumors that are hard to remove without major pelvic surgery.
This trial studies nivolumab, an immune therapy, for skin squamous cell cancer that can’t be cured with surgery or radiation. It aims to see how well the treatment shrinks tumors and helps people live longer or longer without cancer growth.
Hear when a new Vulvar Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.